Lexeo Therapeutics expected to post Q2 2024 EPS of ($0.65) with a consensus target price of $21.00, suggesting a 19.45% upside.
Lexeo Therapeutics (LXEO) has a consensus target price of $21.00, indicating a potential upside of 19.45%. In a report issued on June 6th, HC Wainwright analyst M. Kapoor anticipates Lexeo Therapeutics will post Q2 2024 earnings of ($0.65) EPS. The company has a debt-to-equity ratio of 0.01 and a current ratio of 9.16. As a group, "Biological products, except diagnostic" companies have a potential upside of 64.65%.
June 12, 2024
3 Articles